Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Apr;61(4):563–567. doi: 10.1038/bjc.1990.126

Enhancement of the radiosensitivity of two human tumour cell lines by hexamethylene bisacetamide.

C A Bill 1, C M Vines 1, K C Garrett 1, K Yamada 1, P J Tofilon 1
PMCID: PMC1971349  PMID: 2331442

Abstract

The effect of the maturation-inducing polar solvent, hexamethylene bisacetamide (HMBA), on the radiosensitivity of two human tumour cell lines (clone A, a colon carcinoma; and EJ, a bladder carcinoma) was investigated. Exposure of clone A or EJ cells to HMBA resulted in a concentration-dependent increase in doubling time, a decreased plating efficiency and changes in cell morphology, which are consistent with the formation of a better-differentiated phenotype. Growth of clone A cells in 2 or 3 mM HMBA, followed by irradiation and plating into HMBA-free medium, resulted in a significant enhancement in radiosensitivity, as determined by colony-forming ability. A similar increase in radiosensitivity was detected for EJ cells; however, for these cells a concentration of 7 mM HMBA was required. The increased radiosensitivity caused by HMBA was observed primarily in the low-dose, shoulder region of the gamma-ray cell survival curves for both cell lines, which is reflected by an increase in the alpha component of the survival curve with essentially no effect on beta. These data indicate that HMBA can radiosensitise human tumour cells at concentrations and for exposure periods that can be achieved in the clinic.

Full text

PDF
563

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arundel C. M., Glicksman A. S., Leith J. T. Enhancement of radiation injury in human colon tumor cells by the maturational agent sodium butyrate (NaB). Radiat Res. 1985 Dec;104(3):443–448. [PubMed] [Google Scholar]
  2. Arundel C. M., Vines C. M., Tofilon P. J. Chromatin modifications associated with N-methylformamide-induced radiosensitization of clone A cells. Cancer Res. 1988 Oct 15;48(20):5669–5673. [PubMed] [Google Scholar]
  3. Arundel C., Bock S., Brock W. A., Tofilon P. J. Radiosensitization of primary human tumor cell cultures by N-methylformamide. Int J Radiat Oncol Biol Phys. 1987 May;13(5):753–757. doi: 10.1016/0360-3016(87)90295-1. [DOI] [PubMed] [Google Scholar]
  4. Bloch A. Induced cell differentiation in cancer therapy. Cancer Treat Rep. 1984 Jan;68(1):199–205. [PubMed] [Google Scholar]
  5. Brindley C., Gescher A., Harpur E. S., Ross D., Slack J. A., Threadgill M. D., Whitby H. Studies of the pharmacology of N-methylformamide in mice. Cancer Treat Rep. 1982 Nov;66(11):1957–1965. [PubMed] [Google Scholar]
  6. Chadwick K. H., Leenhouts H. P. A molecular theory of cell survival. Phys Med Biol. 1973 Jan;18(1):78–87. doi: 10.1088/0031-9155/18/1/007. [DOI] [PubMed] [Google Scholar]
  7. Chun H. G., Leyland-Jones B., Hoth D., Shoemaker D., Wolpert-DeFilippes M., Grieshaber C., Cradock J., Davignon P., Moon R., Rifkind R. Hexamethylene bisacetamide: a polar-planar compound entering clinical trials as a differentiating agent. Cancer Treat Rep. 1986 Aug;70(8):991–996. [PubMed] [Google Scholar]
  8. Conley B. A., Forrest A., Egorin M. J., Zuhowski E. G., Sinibaldi V., Van Echo D. A. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580). Cancer Res. 1989 Jun 15;49(12):3436–3440. [PubMed] [Google Scholar]
  9. Deacon J., Peckham M. J., Steel G. G. The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother Oncol. 1984 Dec;2(4):317–323. doi: 10.1016/s0167-8140(84)80074-2. [DOI] [PubMed] [Google Scholar]
  10. Denekamp J. Cell kinetics and radiation biology. Int J Radiat Biol Relat Stud Phys Chem Med. 1986 Feb;49(2):357–380. doi: 10.1080/09553008514552591. [DOI] [PubMed] [Google Scholar]
  11. Dexter D. L., Lee E. S., Bliven S. F., Glicksman A. S., Leith J. T. Enhancement by N-methylformamide of the effect of ionizing radiation on a human colon tumor xenografted in nude mice. Cancer Res. 1984 Nov;44(11):4942–4946. [PubMed] [Google Scholar]
  12. Egorin M. J., Sigman L. M., Van Echo D. A., Forrest A., Whitacre M. Y., Aisner J. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. Cancer Res. 1987 Jan 15;47(2):617–623. [PubMed] [Google Scholar]
  13. Fertil B., Malaise E. P. Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy. Int J Radiat Oncol Biol Phys. 1981 May;7(5):621–629. doi: 10.1016/0360-3016(81)90377-1. [DOI] [PubMed] [Google Scholar]
  14. Hughes E. H., Schut H. A., Thorgeirsson S. S. Effects of hexamethylene bisacetamide on alpha-fetoprotein, albumin, and transferrin production by two rat hepatoma cell lines. In Vitro. 1982 Feb;18(2):157–164. doi: 10.1007/BF02796408. [DOI] [PubMed] [Google Scholar]
  15. Iwakawa M., Milas L., Hunter N., Tofilon P. J. Modification of tumor and normal tissue radioresponse in mice by N-methylformamide. Int J Radiat Oncol Biol Phys. 1987 Jan;13(1):55–60. doi: 10.1016/0360-3016(87)90260-4. [DOI] [PubMed] [Google Scholar]
  16. Johnston D. A., White R. A., Barlogie B. Automatic processing and interpretation of DNA distributions: comparison of several techniques. Comput Biomed Res. 1978 Aug;11(4):393–404. doi: 10.1016/0010-4809(78)90020-4. [DOI] [PubMed] [Google Scholar]
  17. Leith J. T., Gaskins L. A., Dexter D. L., Calabresi P., Glicksman A. S. Alteration of the survival response of two human colon carcinoma subpopulations to x-irradiation by N,N-dimethylformamide. Cancer Res. 1982 Jan;42(1):30–34. [PubMed] [Google Scholar]
  18. Leith J. T., Lee E. S., Leite D. V., Glicksman A. S. Enhanced X ray sensitivity of human colon tumor cells by combination of N-methylformamide with chemotherapeutic agents. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1423–1427. doi: 10.1016/0360-3016(86)90186-0. [DOI] [PubMed] [Google Scholar]
  19. Leith J. T., Lee E. S., Vayer A. J., Jr, Dexter D. L., Glicksman A. S. Enhancement of the responses of human colon adenocarcinoma cells to X-irradiation and cis-platinum by N-methylformamide (NMF). Int J Radiat Oncol Biol Phys. 1985 Nov;11(11):1971–1976. doi: 10.1016/0360-3016(85)90279-2. [DOI] [PubMed] [Google Scholar]
  20. Malaise E. P., Fertil B., Deschavanne P. J., Chavaudra N., Brock W. A. Initial slope of radiation survival curves is characteristic of the origin of primary and established cultures of human tumor cells and fibroblasts. Radiat Res. 1987 Aug;111(2):319–333. [PubMed] [Google Scholar]
  21. Reuben R. C., Wife R. L., Breslow R., Rifkind R. A., Marks P. A. A new group of potent inducers of differentiation in murine erythroleukemia cells. Proc Natl Acad Sci U S A. 1976 Mar;73(3):862–866. doi: 10.1073/pnas.73.3.862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Spremulli E. N., Dexter D. L. Polar solvents: a novel class of antineoplastic agents. J Clin Oncol. 1984 Mar;2(3):227–241. doi: 10.1200/JCO.1984.2.3.227. [DOI] [PubMed] [Google Scholar]
  23. Tofilon P. J., Vines C. M., Bill C. A. Enhancement of radiation-induced DNA double-strand breaks and micronuclei in human colon carcinoma cells by N-methylformamide. Radiat Res. 1989 Jul;119(1):166–175. [PubMed] [Google Scholar]
  24. Young C. W., Fanucchi M. P., Declan Walsh T., Baltzer L., Yaldaei S., Stevens Y. W., Gordon C., Tong W., Rifkind R. A., Marks P. A. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals. Cancer Res. 1988 Dec 15;48(24 Pt 1):7304–7309. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES